Trial site
Neurological Institute Foundation Casimiro Mondino
Pavia, PV 27100, ItalyNot linked to an institution yet
- 10running trials
- 13closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 24 trials
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed13 trials
- Active, not recruiting6 trials
- Recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- AbbVie3 trials
- Hoffmann-La Roche3 trials
- Eli Lilly & Co.2 trials
- H. Lundbeck A/S2 trials
- Janssen Research & Development, LLC2 trials
- and 9 more
Running trials
Not yet recruiting
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
NCT07474779· University of Pavia· Source
Contact: Micol Avenali, MD, PhD
Recruiting
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
NCT06126315· Phase 2/3· Mario Negri Institute for Pharmacological Research· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Active, not recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· Phase 3· Sanofi· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172· Phase 3· H. Lundbeck A/S· Source
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Active, not recruiting
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
NCT06315322· Phase 3· UCB Biopharma SRL· Source
Completed
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· Phase 3· AbbVie· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· Phase 3· Ipsen· Source
Completed
An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.
2023-503678-18-00· Phase 2· Bioprojet Pharma· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· AbbVie· Source
Completed
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
NCT05798520· Phase 2· Biogen· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
NCT05452239· Phase 4· H. Lundbeck A/S· Source
Completed
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616· Phase 2· UCB Biopharma SRL· Source
Completed
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· Phase 3· AbbVie· Source
Completed
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)
NCT04396574· Phase 3· Eli Lilly & Co.· Source
Completed
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With
Migraine (PIONEER-PEDS1)
NCT04396236· Phase 3· Eli Lilly & Co.· Source
Report an error